18 October 2021
By ending its ambivalence towards the protection of IP rights, the government can bridge the gap towards achieving its aspirations to be a globally competitive, high-income knowledge-economy.
Tag: intellectual property
29 July 2020
Charles Santiago says Malaysians can’t afford the total remdesivir price of RM10,000 per patient.
26 May 2020
Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
20 May 2020
Today, the patent system in pharmaceuticals all too often restricts the open sharing of information, prevents further innovation by others through unjustified extensions of patents, and disincentivises real innovation.
20 May 2020
The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements are Malaysia, Singapore, and Brunei.
1 April 2020
Letter
Cooperation, Not Coercion Is The Key To New Covid-19 Treatments And Cures – Philip Stevens & Mark Schultz
The existence of IP rights has enabled a rapid response by the private sector.
2 March 2020
The Pharmaceutical Research and Manufacturers of America wants the Trump administration to reverse compulsory licensing in Malaysia and end "discriminatory" market access practices.
10 October 2019
Malaysia and other ASEAN countries have many strengths that can transform them into global innovation leaders.
20 September 2019
Voluntary licences can lead to an extra 54 to 69 people annually receiving Hepatitis C treatment per 1,000 individuals diagnosed.
8 July 2019
Malaysia’s ROSE system makes it easy for women to get screened for cervical cancer. Like all digital health systems, it could not function without IP.